Hematology
From the Journals
‘Highly encouraging’ MRD results for zanubrutinib add-on in CLL
Blood and bone marrow MRD was undetectable in almost 90% of subjects after a median of 10 treatment cycles.
News from the FDA/CDC
Voxelotor for sickle cell anemia now down to 4-year-olds
Conference Coverage
Fitusiran: Great ‘leap forward’ in hemophilia treatment
Cost will be a major consideration if fitusiran is approved for the U.S. market.
News from the FDA/CDC
CDC panel backs mRNA COVID vaccines over J&J because of clot risk
The risk of dying from TTS after a Johnson & Johnson shot is extremely rare.
Conference Coverage
Telemedicine helps SCD patients survive COVID, but more need access
The second COVID-19 wave brought zero deaths and fewer complicated hospitalizations at the largest U.S. adult sickle cell disease center, but care...
Latest News
Delayed umbilical cord clamping improves outcomes in very preterm infants
Delayed clamping reduced risk of death or disability by 17% at 2 years of age.
Conference Coverage
Beta-thalassemia gene therapy achieves lasting transfusion independence
“Seeing the restoration of iron metabolism, it really takes us a step closer to really thinking the term ‘cure’ might truly apply.”
From the Journals
Apixaban outmatches rivaroxaban for VTE in study
These real-world findings may guide selection of initial anticoagulant therapy, according to authors of the paper.
Latest News
Risk-based antenatal type-and-screen blood testing safe and economical
“In a year of selective type and screen, we saw a 51% reduction in costs related to type and screen, and a 38% reduction in overall transfusion-...
From the Journals
Antithrombotic therapy not warranted in COVID-19 outpatients
In stable patients with COVID-19, use of aspirin or apixaban did not reduce the rate of the composite of all-cause mortality, thromboembolism, MI...
From the Journals
Rivaroxaban’s single daily dose may lead to higher bleeding risk than other DOACs
Corroborating previous studies, Iceland researchers report that rivaroxaban poses the highest risk of GI bleeding, compared with other DOACs.